Overview

Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

Status:
Not yet recruiting
Trial end date:
2021-09-18
Target enrollment:
Participant gender:
Summary
A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Phase I Clinical Study to Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers
Phase:
Phase 1
Details
Lead Sponsor:
Hengenix Biotech Inc
Collaborators:
Sanyou Biopharmaceuticals(Shanghai)Co., Ltd
Shanghai ZJ Bio-Tech Co., Ltd
Treatments:
Antibodies, Monoclonal
Myeloma Proteins
Paraproteins